sr9009 sr9009 sr9009, also known as stenabolic, is a research drug that was developed by professor thomas burris of the scripps research institute as an agonist of rev-erba (i.e., increases the constitutive repression of genes regulated by rev-erba) with a half-maximum inhibitory concentration (ic50) = 670 nm for rev-erbaα and ic50 = 800 nm for rev-erbaβ. sr9009identifiers iupac name ethyl-3-(((4-chlorobenzyl)((5-nitrothiophen-2-yl)methyl)amino)methyl)pyrrolidine-1-carboxylate cas number1379686-30-2pubchem cid57394020chemspider28487410uniix5dca09n30chemblchembl1961796chemical and physical dataformulac20h24cln3o4smolar mass437.94026 g·mol−13d model (jsmol)interactive image smiles ccoc(=o)n1ccc(c1)cn(cc2=cc=c(c=c2)cl)cc3=cc=c(s3)(=o) inchi inchi=1s/c20h24cln3o4s/c1-2-28-20(25)23-10-9-16(13-23)12-22(11-15-3-5-17 (21)6-4-15)14-18-7-8-19(29-18)24(26)27/h3-8,16h,2,9-14h2,1h3key:mmjjnhoivcgaap-uhfffaoysa-n activation of rev-erba-α by sr9009 in mice increases exercise capacity by increasing mitochondria counts in skeletal muscle. abuse of sr9009 has been reported within the bodybuilding community, resulting in sr9009 being placed on the world anti-doping agency list of prohibited drugs. sr9009 and the related sr9011 drug are described as "hormone and metabolic modulators".